16154-78-2

Pirlindole作为一种可逆的单胺氧化酶A (RIMA) 抑制剂，主要在俄罗斯作为抗抑郁化合物开发并使用。它在结构和药理学上与metralindole相似。Pirlindole已在一些欧洲和非欧洲国家批准用于治疗抑郁症。其口服绝对生物利用度为20%至30%，主要因为显著的首过效应。对于大鼠而言，其口服Tmax在2.5至6小时之间变化；对于狗，该值在0.8至2小时之间。

Pirlindole-D4 hydrochloride is intended for use as an internal standard for the quantification of pirlindole by GC- or LC-MS. Pirlindole is a selective and reversible monoamine oxidase A (MAO-A)inhibitor. It is selective for MAO-A over MAO-B. In rats,it reverses the depressive-like effects induced by chronic mild stress (CMS),increases proliferation of hippocampal neural progenitor cells,and reverses dendritic atrophy in granule neurons. Pirlindole is also an inhibitor of enterovirus-D68 and coxsackievirus B3 (CV-B3),inhibiting the genome replication phase of CV-B3 infection with an EC50 value of 7.7 µM independent of MAO-A activity.